Cardinal Health (CAH)
(Delayed Data from NYSE)
$102.58 USD
+1.92 (1.91%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $102.37 -0.21 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.58 USD
+1.92 (1.91%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $102.37 -0.21 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
Looking for a Growth Stock? 3 Reasons Why Cardinal (CAH) is a Solid Choice
by Zacks Equity Research
Cardinal (CAH) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Buy Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
5 Top Recession-Proof Dividend Stocks to Buy in 2023
by Tirthankar Chakraborty
Investors should place their bets now on dividend-paying recession-proof stocks such as Cardinal Health (CAH), Conagra Brands (CAG), Ingredion (INGR), Atmos Energy (ATO) and NRG Energy (NRG) for a steady income.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Retain Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.
5 Stocks in S&P 500 ETF With 40% Gains in 2022
by Sweta Killa
The S&P 500 wrapped up its worst year since 2008, tumbling 20%. Persistently high inflation, a hawkish Fed, Russia's invasion of Ukraine and a resurgence of COVID-19 cases in China weighed heavily on investor sentiment.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
by Zacks Equity Research
Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Zacks.com featured highlights include Archer-Daniels-Midland, Cardinal Health, Insperity, Deere & Co. and H&R Block
by Zacks Equity Research
Archer-Daniels-Midland, Cardinal Health, Insperity, Deere & Co. and H&R Block are part of the Zacks Screen of the Week.
What Makes Cardinal Health (CAH) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
5 Top-Ranked Dividend Growth Stocks for 2023
by Sweta Killa
Archer-Daniels-Midland (ADM), Cardinal Health (CAH), Insperity (NSP), Deere & Company (DE), and H&R Block (HRB) could be compelling picks for 2023.
5 Broker-Friendly Stocks to Bank On as Volatility Persists
by Maharathi Basu
Broker-favorite stocks like Cardinal Health (CAH), American Airlines (AAL), Boise Cascade (BCC), AmerisourceBergen (ABC) and Centene (CNC) should be on an investors' watchlist.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Top S&P 500 Performers of 2022
by Derek Lewis
Investors are more than aware of how harsh the market has been in 2022, with many stocks residing in the red year-to-date. Still, these three stocks have snapped the bearish trend, delivering substantial gains to shareholders.
3 Reasons Why Cardinal (CAH) Is a Great Growth Stock
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
3 Medical Stocks Creating Wealth Despite Macro Challenges
by Indrajit Bandyopadhyay
Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
The Zacks Analyst Blog Highlights Enphase Energy, Halliburton, Cardinal Health and W.R. Berkley
by Zacks Equity Research
Enphase Energy, Halliburton, Cardinal Health and W.R. Berkley are included in this Analyst Blog.